Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 4/20 | 0.41 |
| ▸ | BTK | Q06187 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.41 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.40 |
| ▸ | PIP4K2B | P78356 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | BLK | P51451 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3C2G | O75747 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469559 | 0.85 | AURKA (0.45) | EGFRERBB2KDRPLCG1ITK | |
| SCHEMBL18948298 | 0.83 | CDK7 (0.35) | BRD4AURKAAURKBPLK4LRRK2 | |
| SCHEMBL17469564 | 0.81 | MAPK7 (0.50) | BRD4AURKAAURKBPLK4LRRK2 | |
| SCHEMBL16065777 | 0.75 | DCLK1 (0.59) | EGFRITKBRD4AURKAAURKB | |
| SCHEMBL16065773 | 0.75 | ITK (0.59) | EGFRITKAURKAAURKBLRRK2 | |
| SCHEMBL20682528 | 0.74 | DCLK1 (0.43) | EGFRITKBRD4AURKAAURKB | |
| SCHEMBL17469527 | 0.73 | CCNK (0.46) | — | |
| SCHEMBL25735908 | 0.68 | BRD4 (0.43) | EGFRERBB2KDRITKBTK | |
| SCHEMBL21443492 | 0.67 | EGFR (0.69) | EGFRERBB2ITKBTKPIP4K2A | |
| SCHEMBL19496540 | 0.66 | MAPK7 (0.49) | BRD4AURKAAURKBLRRK2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3738964-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9676792-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | EGFR 662/4885ERBB2 125/4885KDR 652/4885 |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | EGFR 662/4885ERBB2 125/4885KDR 652/4885 |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | EGFR 662/4885ERBB2 125/4885KDR 652/4885 |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | EGFR 662/4885ERBB2 125/4885KDR 652/4885 |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | EGFR 662/4885ERBB2 125/4885KDR 652/4885 |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | EGFR 662/4885ERBB2 125/4885KDR 652/4885 |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | EGFR 662/4885ERBB2 125/4885KDR 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.